Effectiveness and duration of a second COVID-19 vaccine booster

Simple item page
dc.catalogadoraba
dc.contributor.authorJara, Alejandro
dc.contributor.authorCuadrado, Cristobal
dc.contributor.authorUndurraga Fourcade, Eduardo Andrés
dc.contributor.authorGarcía, Christian
dc.contributor.authorNajera, Manuel
dc.contributor.authorBertoglia, María Paz
dc.contributor.authorVergara, Verónica
dc.contributor.authorFernández, Jorge
dc.contributor.authorGarcía, Heriberto
dc.contributor.authorAraos, Rafael
dc.date.accessioned2023-08-11T22:05:39Z
dc.date.available2023-08-11T22:05:39Z
dc.date.issued2022
dc.description.abstractUsing a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluated the effectiveness against COVID-19 related ICU admissions and death of mRNA-based second vaccine boosters for four different three-dose background regimes: BNT162b2 primary series plus a homologous booster, and CoronaVac primary series plus an mRNA booster, a homologous booster, and a ChAdOx-1 booster. We estimated the vaccine effectiveness weekly from February 14 to August 15, 2022, by estimating hazard ratios of immunization over non-vaccination, accounting for relevant confounders. The overall adjusted effectiveness of a second mRNA booster shot was 88.2% (95%CI, 86.2-89.9) and 90.5% (95%CI 89.4-91.4) against ICU admissions and death, respectively. Vaccine effectiveness showed a mild decrease for all regimens and outcomes, probably associated with the introduction of BA.4 and BA.5 Omicron sub-lineages and immunity waning. The duration of effectiveness suggests that no additional boosters are needed six months following a second booster shot.
dc.fechaingreso.objetodigital2024-06-07
dc.format.extent32 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1101/2022.10.03.22280660
dc.identifier.urihttps://doi.org/10.1101/2022.10.03.22280660
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/74389
dc.information.autorucFacultad de Matemáticas; Jara, Alejandro; 0000-0002-2282-353X; 127927
dc.information.autorucEscuela de Gobierno; Undurraga Fourcade, Eduardo Andrés; 0000-0002-4425-1253; 12868
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final32
dc.pagina.inicio1
dc.revistamedRxiv
dc.rightsacceso abierto
dc.rights.licenseAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.es
dc.subjectSARS-CoV-2es_ES
dc.subjectCOVID-19es_ES
dc.subjectVaccinees_ES
dc.subjectImmunizationes_ES
dc.subjectBoosterses_ES
dc.subjectLong-term vaccine effectivenesses_ES
dc.subjectOmicrones_ES
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEffectiveness and duration of a second COVID-19 vaccine booster
dc.typepreprint
sipa.codpersvinculados127927
sipa.codpersvinculados12868
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2022.10.03.22280660v1.full.pdf
Size:
1.58 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas